Products
Companies
News
About
About
Add your product
Contact
Newsletter
×
Subscribe to our monthly newsletter
Subscribe
Products
AIRAscore structure
AIRAscore structure
AIRAmed
AIRAscore structure provides quantitative data of brain tissue and brain structures for early detection of atrophies and tracking progression. In addition, the lesion characterisation and quantification may support the diagnosis of a wide range of neurodegenerative diseases. The results are presented in the PACS as a PDF report and compared to an age- and sex-correlated reference collective. Bar charts and a pictogram-based spatial representation of the results facilitate their interpretation.
Information source:
Vendor
Last updated:
Sept. 29, 2023
General Information
Technical Specifications
Regulatory
Market
Evidence
General Information
General
Product name
AIRAscore structure
Company
AIRAmed
Subspeciality
Neuro
Modality
MR
Disease targeted
Neurodegenerative diseases, e.g. dementia, Alzheimer’s disease, multiple sclerosis, Parkinson’s Disease
Key-features
Brain tissue and anatomy segmentation, volume quantification, normative comparison, report generation, WMH detection and quantification
Suggested use
During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand)
Technical Specifications
Data characteristics
Population
All with suspicion of or in treatment of neurodegenerative disease
Input
3DT1 MRI, 3D or 2D T2 FLAIR, 1.5 or 3T
Input format
DICOM
Output
Table of quantified values, bar charts and a pictogram-based spatial representation of the values, PDF-report, segmentation overlays
Output format
DICOM, DICOM-PDF
Technology
Integration
Integration in standard reading environment (PACS)
Deployment
Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis
On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time
1 - 10 minutes
Regulatory
Certification
CE
Certified, Class I
, MDD
FDA
510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)
Market
Market presence
On market since
08-2020
Distribution channels
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model
Pay-per-use
Based on
Number of analyses
Evidence
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers